Search form


Press Releases

Axcan Announces Conference Call And Web Cast For First Quarter Of Fiscal 2004 Results

Jan 26, 2004 - 12:00 ET

Axcan Announces Conference Call And Web Cast For First Quarter Of Fiscal 2004 Results 

MONT SAINT-HILAIRE, Quebec--Axcan Pharma Inc. ("Axcan" or the "Company")
today announced that it will report first quarter of fiscal 2004 financial
results on Thursday, February 5, 2004.

Axcan will host a conference call at 4:30 P.M. EST, on Thursday, February 5, 2004.
Interested parties may also access the conference call by web cast at
The web cast will be archived for 90 days.

The telephone numbers to access the conference call are
(800) 814-4859 (Canada and United States) or (416) 640-4127 (international).
A replay of the call will be available until February 12, 2004.
The telephone number to access the replay of the call is (416) 640-1917
code: 21035576.

Axcan is a leading specialty pharmaceutical company involved in the field of
gastroenterology. Axcan markets a broad line of prescription products sold for
the treatment of symptoms in a number of gastrointestinal diseases and disorders
such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver
diseases and complications related to cystic fibrosis. Axcan's products are
marketed by its own sales force in North America and Europe. Its common shares are
listed on the Toronto Stock Exchange under the symbol AXP and on the NASDAQ
National Market under the symbol "AXCA".

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. 

To the extent any statements made in this release contain information that is
not historical, these statements are essentially forward looking and are subject to
risks and uncertainties, including the difficulty of predicting FDA approvals,
acceptance and demand for new pharmaceutical products, the impact of competitive
products and pricing, new product development and launch, reliance on key strategic
alliances, availability of raw materials, the regulatory environment, fluctuations
in operating results and other risks detailed from time to time in the company's
filings with the Securities and Exchange Commission.

David W. Mims
Executive Vice President and Chief Operating Officer
Axcan Pharma Inc.
Tel: (205) 991-8085 ext. 223

Isabelle Adjahi
Director, Investor Relation
Axcan Pharma Inc.
Tel: (450) 467-2600 ext. 2000